A Phase I, Open-label Trial to Investigate the Metabolism, Pharmacokinetics (Following a Mass Balance Design; Part A) and Absolute Bioavailability of BI 1839100 (C-14) After Oral and Intravenous Administration (Part B) in Healthy Male Subjects
Latest Information Update: 30 Aug 2024
At a glance
- Drugs BI 1839100 (Primary) ; BI 1839100 (Primary)
- Indications Pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 30 Aug 2024 New trial record